Deal Watch: Lilly Takes Global Rights To Centrexion Non-Opioid Pain Candidate

 
• By Joseph Haas and Eleanor Malone

Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.

DealWatch_1200x675
New deals by Lilly and Viela lead this edition of Deal Watch

More from Deals

More from Business